Compare Fidelity National Information Servcs Inc (FIS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Moderna, Inc. — how do they compare? Fidelity National Information Servcs Inc trades at $42.07 (market cap $22.05B), while Moderna, Inc. trades at $60.75 (market cap $24.18B). The key difference: Fidelity National Information Servcs Inc and Moderna, Inc. are close in size by market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| FIS | MRNA | |
|---|---|---|
Market Cap | $22.05B | $24.18B |
Sector | Technology | Health |
52-Week High | $72.77 | $81.80 |
52-Week Low | $37.72 | $22.36 |
Enterprise Value | $42.56B | $20.33B |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.51, down 0.61% today. The stock shows mixed signals with a bearish technical trend but strong fundamentals, including a low P/E of 6.57 and robust ROE of 22.33%. Recent Q2 2026 earnings beat expectations, driven by Banking Solutions growth, though full-year guidance was trimmed. Positive news includes global platform expansions in APAC and industry recognition for treasury software.
The outlook is cautiously optimistic. Attractive valuation and profitability metrics present an opportunity, but risks include execution challenges in Capital Markets and competitive pressures. Analyst consensus is strongly Buy with a $50.18 price target, suggesting significant upside potential from current levels if growth initiatives succeed.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
